Polyglycerol‐Based Lipids: A Next‐Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems
Macromolecular Rapid Communications · 2026
DOI: 10.1002/marc.202500428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Rapid Communications, 2026. Verfasst von Yara Ensminger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute For Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Glycerol, Polymers. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Polyethylene glycol (PEG) is widely used to provide a stealth effect in various therapeutic applications. However, an increased occurrence of anti‐PEG antibodies in patients can lead to immunological side effects and accelerated blood clearance, reducing the efficiency of PEG‐based delivery vectors. One of these PEG‐containing vectors is lipid nanoparticles (LNPs), which effectively deliver nucleic acids. Their high potential for treating a great number of diseases in the future was already showcased in the mRNA vaccines developed during the COVID‐19 pandemic. Thus, the aim of our study was to formulate LNP systems utilizing linear polyglycerol (lPG) as an alternative stealth polymer to avoid anti‐PEG antibodies while enabling mRNA delivery. Our study showed that lPG‐functionalized LNPs had negligible binding to IgG anti‐PEG antibodies, while successfully delivering eGFP mRNA into HepG2 cells with comparable transfection efficiency as PEGylated LNPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute For Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
- Chemical and Pharmaceutical Development, Bayer AG Pharmaceuticals, Berlin, Germany.
- Drug Discovery Sciences, Bayer AG Pharmaceuticals, Wuppertal, Germany.
ORCID-Profile: Gideon Nölte, Rainer Haag
Förderung
- German Research Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Ensminger, Y., Rashmi, R., Karimov, M., Nölte, G., Hafke, M., Schmitt, A. C., Díaz-Oviedo, D., Köbberling, J., & Haag, R. (2026). Polyglycerol‐Based Lipids: A Next‐Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems. Macromolecular Rapid Communications. https://doi.org/10.1002/marc.202500428
Vancouver
Ensminger Y, Rashmi R, Karimov M, Nölte G, Hafke M, Schmitt AC, et al. Polyglycerol‐Based Lipids: A Next‐Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems. Macromolecular Rapid Communications. 2026. doi:10.1002/marc.202500428
BibTeX
@article{Ensminger2026,
author = {Ensminger, Yara and Rashmi, Rashmi and Karimov, Michael and Nölte, Gideon and Hafke, Markus and Schmitt, Ann-Cathrin and Díaz-Oviedo, David and Köbberling, Johannes and Haag, Rainer},
title = {Polyglycerol‐Based Lipids: A Next‐Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems},
journal = {Macromolecular Rapid Communications},
year = {2026},
doi = {10.1002/marc.202500428}
}
EUVIMED